StockNews.com Begins Coverage on vTv Therapeutics (NASDAQ:VTVT)

Investment analysts at StockNews.com assumed coverage on shares of vTv Therapeutics (NASDAQ:VTVT) in a note issued to investors on Wednesday. The firm set a “sell” rating on the biotechnology company’s stock.

Separately, Alliance Global Partners started coverage on shares of vTv Therapeutics in a research note on Monday, December 9th. They issued a “buy” rating and a $35.00 target price for the company.

vTv Therapeutics Trading Down 7.7 %

Shares of NASDAQ VTVT opened at $20.99 on Wednesday. vTv Therapeutics has a 1-year low of $12.12 and a 1-year high of $30.99. The company has a market cap of $66.96 million, a PE ratio of -4.63 and a beta of 1.07. The company has a 50-day moving average of $16.76 and a two-hundred day moving average of $15.40.

Institutional Investors Weigh In On vTv Therapeutics

Institutional investors and hedge funds have recently modified their holdings of the business. FMR LLC bought a new stake in shares of vTv Therapeutics during the third quarter worth approximately $2,402,000. JPMorgan Chase & Co. bought a new stake in shares of vTv Therapeutics during the fourth quarter worth approximately $25,000. Finally, Geode Capital Management LLC raised its stake in shares of vTv Therapeutics by 12.9% during the fourth quarter. Geode Capital Management LLC now owns 11,634 shares of the biotechnology company’s stock worth $158,000 after buying an additional 1,327 shares during the last quarter. 17.51% of the stock is owned by institutional investors.

About vTv Therapeutics

vTv Therapeutics Inc, a clinical stage biopharmaceutical company, focuses on the development of orally administered treatments for metabolic and inflammatory diseases. The company's lead drug candidate is cadisegliatin (TTP399), an orally administered small molecule and liver-selective glucokinase activator that is in Phase III clinical trial for treating type 1 and type 2 diabetes; and TTP273, an orally available small molecule glucagon-like peptide 1 receptor agonists that is in Phase I clinical trial for the treatment of cystic fibrosis related diabetes, as well as in Phase II trial for the treatment of type 2 diabetes.